206 related articles for article (PubMed ID: 27435393)
41. Angiogenesis Driven by the CEBPD-hsa-miR-429-VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression.
Chan TC; Hsing CH; Shiue YL; Huang SK; Hsieh KL; Kuo YH; Li CF
Cells; 2022 Feb; 11(4):. PubMed ID: 35203290
[TBL] [Abstract][Full Text] [Related]
42. Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells.
Ge X; Chen Q; Wu YP; Zhang Y; Xia H; Yuan D; Chen Q; Leng W; Chen L; Tang Q; Pang X; Bi F
Oncol Rep; 2014 Oct; 32(4):1401-8. PubMed ID: 25198583
[TBL] [Abstract][Full Text] [Related]
43. Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations.
Lacroix L; Pautier P; Duvillard P; Motté N; Saulnier P; Bidart JM; Soria JC
Int J Cancer; 2006 Feb; 118(4):1068-9. PubMed ID: 16152583
[No Abstract] [Full Text] [Related]
44. Transactivation of PTGS2 by PAX5 signaling potentiates cisplatin resistance in muscle-invasive bladder cancer cells.
Dong BW; Zhang WB; Qi SM; Yan CY; Gao J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2293-2300. PubMed ID: 29964012
[TBL] [Abstract][Full Text] [Related]
45. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.
Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y
Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922
[TBL] [Abstract][Full Text] [Related]
46. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
[TBL] [Abstract][Full Text] [Related]
47. The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer.
Chuang CH; Wang WJ; Li CF; Ko CY; Chou YH; Chuu CP; Cheng TL; Wang JM
Cell Death Dis; 2014 May; 5(5):e1220. PubMed ID: 24810056
[TBL] [Abstract][Full Text] [Related]
48. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
[TBL] [Abstract][Full Text] [Related]
49. Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.
Chi JY; Hsiao YW; Li CF; Lo YC; Lin ZY; Hong JY; Liu YM; Han X; Wang SM; Chen BK; Tsai KK; Wang JM
Oncotarget; 2015 Sep; 6(27):23987-4001. PubMed ID: 26124179
[TBL] [Abstract][Full Text] [Related]
50. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y
Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284
[TBL] [Abstract][Full Text] [Related]
51. YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells.
Ooki A; Del Carmen Rodriguez Pena M; Marchionni L; Dinalankara W; Begum A; Hahn NM; VandenBussche CJ; Rasheed ZA; Mao S; Netto GJ; Sidransky D; Hoque MO
Cancer Res; 2018 Jan; 78(1):168-181. PubMed ID: 29180467
[TBL] [Abstract][Full Text] [Related]
52. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
Jin HO; Lee YH; Park JA; Kim JH; Hong SE; Kim HA; Kim EK; Noh WC; Kim BH; Ye SK; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
Biochem Biophys Res Commun; 2014 Feb; 444(4):502-8. PubMed ID: 24472538
[TBL] [Abstract][Full Text] [Related]
53. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.
Liang PI; Wu LC; Sheu JJ; Wu TF; Shen KH; Wang YH; Wu WR; Shiue YL; Huang HY; Hsu HP; Chen YH; Chen LT; Li CF; Liao AC
J Clin Pathol; 2012 Sep; 65(9):802-7. PubMed ID: 22685262
[TBL] [Abstract][Full Text] [Related]
54. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
55. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
[TBL] [Abstract][Full Text] [Related]
56. The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells.
Kang Y; Park MA; Heo SW; Park SY; Kang KW; Park PH; Kim JA
Biochim Biophys Acta; 2013 Mar; 1830(3):2638-48. PubMed ID: 23246576
[TBL] [Abstract][Full Text] [Related]
57. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
58. Shikonin inhibits CEBPD downregulation in IL‑17‑treated HaCaT cells and in an imiquimod‑induced psoriasis model.
Lan XO; Wang HX; Qi RQ; Xu YY; Yu YJ; Yang Y; Guo H; Gao XH; Geng L
Mol Med Rep; 2020 Sep; 22(3):2263-2272. PubMed ID: 32705251
[TBL] [Abstract][Full Text] [Related]
59. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
Menendez JA; Mehmi I; Lupu R
J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
[TBL] [Abstract][Full Text] [Related]
60. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.
Lo HW; Cao X; Zhu H; Ali-Osman F
Clin Cancer Res; 2008 Oct; 14(19):6042-54. PubMed ID: 18829483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
